People familiar with the negotiations say AbbVie is in advanced talks to acquire Revolution Medicines, a cancer-drug developer with a market capitalization of approximately $16 billion. The deal, if completed, would bolster AbbVie’s oncology pipeline, adding Revolution’s late-stage small-molecule inhibitors targeting KRAS and other oncogenic drivers. Advisors on both sides are reportedly finalizing terms, with expectations that a definitive agreement could be announced in the first quarter of 2026. Investors view the potential acquisition as a strategic move to offset patent expirations on key immunology products and diversify revenue streams into high-growth oncology franchises.

AbbVie has confirmed that it will release its full-year and fourth-quarter 2025 results on Wednesday, February 4, 2026, before markets open. The company will host a live webcast of its earnings conference call at 8 a.m. Central time, accessible via its Investor Relations website. Management is expected to discuss revenue growth driven by strong uptake of next-generation immunology therapies, progress in neuroscience research programs, and initial contributions from the Allergan Aesthetics portfolio. An archived replay of the call will be available later that day, allowing analysts to assess guidance for 2026 and capital allocation priorities, including R&D investment and potential shareholder returns.

Analysis of AbbVie’s share performance highlights seven rallies exceeding 30% within two-month spans over the past decade, with one surge surpassing 50% in under eight weeks during 2020. Notable multi-month rallies also occurred in 2017 and 2024, driven by positive clinical data releases and favorable regulatory approvals. Market strategists note that triggers for future breakouts could include confirmed deal closure for Revolution Medicines, stronger-than-expected earnings metrics in February, or unexpected clinical trial readouts in AbbVie’s oncology and neuroscience pipelines.